Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?

about

Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?

Item

http://www.wikidata.org/entity/Q57175296

description

article

@en

im Juli 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в липні 2018

@uk

name

Health status decline in α-1 a ...... r disease modifying therapies?

@en

Health status decline in α-1 a ...... r disease modifying therapies?

@nl

type

Item

label

Health status decline in α-1 a ...... r disease modifying therapies?

@en

Health status decline in α-1 a ...... r disease modifying therapies?

@nl

prefLabel

Health status decline in α-1 a ...... r disease modifying therapies?

@en

Health status decline in α-1 a ...... r disease modifying therapies?

@nl

P1476

Health status decline in α-1 a ...... r disease modifying therapies?

@en

P2093

Robert A Stockley

http://www.w3.org/2001/XMLSchema#string

Sian Starkey

http://www.w3.org/2001/XMLSchema#string

P2860

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.

Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Assessing regression to the mean effects in health care initiatives.

Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.

Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?

Club cell protein 16 and disease progression in chronic obstructive pulmonary disease.

Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.

P2888

s12931-018-0844-6

P304

137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12931-018-0844-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alice M. Turner

Ross G Edgar

P577

2018-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105735541

http://www.w3.org/2001/XMLSchema#string

P698

30029692

http://www.w3.org/2001/XMLSchema#string

P932

6053712

http://www.w3.org/2001/XMLSchema#string